Introduction
============

Patients with acute coronary syndrome (ACS) are at higher risk of mortality, especially those suffering from acute myocardial infarction (AMI), which commonly appears as a large amount of necrotic myocardium, making it easier for severe complications to occur.[@b1-dddt-13-719] Since the rapidly developed interventional techniques that have been widely applied in clinic, improved clinical outcomes have been reported.[@b2-dddt-13-719] According to the 2018 European Society of Cardiology (ESC)--European Association for Cardio-Thoracic Surgery (EACTS) guidelines, percutaneous coronary intervention (PCI) was strongly recommended for patients with high-risk ACS (class I).[@b3-dddt-13-719] Of note, a successful PCI procedure would strengthen these benefits, as well as routine dual-antiplatelet treatment (DAPT) consisting of aspirin and a P2Y12-receptor antagonist (clopidogrel),[@b4-dddt-13-719] which might prevent the subsequence of stent thrombosis (ST) or restenosis mainly resulting from the superimposition of a platelet-rich thrombus.[@b5-dddt-13-719] In fact, though routine DAPT following PCI had been widely applied, ST incidence is still high among these patients, because it remains difficult to overcome high on-treatment platelet reactivity (HTPR).[@b6-dddt-13-719]

Ticagrelor is a new, reversible, and direct-acting oral P2Y12 ADP-receptor antagonist, which has been reported to provide faster and greater inhibiting effects on platelet aggregation than clopidogrel.[@b7-dddt-13-719],[@b8-dddt-13-719] As such, it is preferred for patients with ACS, mainly based on results from the PLATO trial, indicating that significantly reduced risk of death from vascular causes, MI, or stroke is found with respect to ticagrelor.[@b9-dddt-13-719] In contrast, another two large randomized controlled trials (RCTs)[@b10-dddt-13-719],[@b11-dddt-13-719] and two observational (Obs) trials[@b12-dddt-13-719],[@b13-dddt-13-719] showed no significant benefits of ticagrelor in reducing the occurrence of ischemic events among these patients. In addition, two recent comprehensive meta-analyses[@b14-dddt-13-719],[@b15-dddt-13-719] also reported antagonistic results of ticagrelor in such patients, but many interfering factors were involved, which might have limited analysis in terms of determining the real efficacy and safety of this new potent oral ADP-receptor antagonist. These conflicting data render the real efficacy and safety of ticagrelor controversial. As a result, we performed this comprehensive meta-analysis involving as many relevant clinical trials as possible to evaluate the efficacy and safety of ticagrelor following PCI for these patients.

Methods
=======

Literature search
-----------------

Electronic databases -- PubMed, MEDLINE, Embase, and the Cochrane Controlled Trials Registry -- were searched for eligible citations (last search was up to October 2018). To make sure all relevant studies would be included, combinations of several relevant keywords were used: "ticagrelor", "clopidogrel", "dual antiplatelet therapy", "DAPT", "acute myocardial infarction OR AMI", "acute coronary syndrome OR ACS", "percutaneous coronary intervention", "PCI" and "stent implantation". Additionally, possible relevant references from published review articles or meta-analyses were hand-searched for eligibility.

Inclusion and exclusion criteria
--------------------------------

Eligible studies needed to meet inclusion criteria of adult patients suffering from ACS (age from 18 to 90 years) and undergoing PCI performed comparisons between ticagrelor and clopidogrel (routine maintenance dose 75 mg) as part of DAPT and follow-up ≥3 months and reported results of adverse clinical events. Exclusion criteria were patients with cardiogenic shock or receiving oral anticoagulants (eg, warfarin, dabigatran, rivaroxaban), ongoing studies, duplicated studies, or different studies using the same sample, non-English-language studies, and review articles or meta-analyses.

Data extraction, synthesis, and quality assessment
--------------------------------------------------

Two independent investigators (ZGF and WLZ) reviewed all relevant citations using standardized data-abstraction forms to assess eligibility. Disagreements were resolved by the third investigator (BX). These extracted data from each included study were study name or authors of the trial, publication year, baseline demographics, characteristics of medical histories, and clinical outcomes during the follow-up. These trials were divided into two subgroups based on the study design: the RCT subgroup and the Obs subgroup. To assess the quality of each retrieved study, the Jadad score[@b16-dddt-13-719] (for RCTs) or the Newcastle--Ottawa Scale[@b17-dddt-13-719] (for Obs trials) was used as appropriate.

Study end points
----------------

The primary end point of this study was incidence of major adverse cardiovascular and cerebrovascular events (MACCEs), consisting of cardiovascular death (all-cause deaths were recorded instead in several trials,[@b10-dddt-13-719],[@b18-dddt-13-719],[@b19-dddt-13-719] due to the absence of relevant data), MI, and stroke. The secondary end point was the risk of definite/probable ST, defined according to the Academic Research Consortium.[@b20-dddt-13-719] The occurrence of bleeding events, including major and minor bleeding, were chosen as the safety end points. There were slight differences with respect to definitions of clinical end points in these trials, and related data were recorded following the standardized definitions.

Statistical analyses
--------------------

The meta-analysis was performed in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analysis) statement.[@b21-dddt-13-719] All end points were recorded as dichotomous variables and relevant comparisons estimated with ORs and 95% CIs. Stata 12.0 (StataCorp, College Station, TX, USA) was used for all statistical analyses, and all *P*-values were two-tailed. Statistical significance was considered when *P*\<0.05. If the *P*-value of Cochrane's *Q* test was \<0.10 and/or the *I*^2^ statistic was ≥50%, significant heterogeneity was considered and a random-effect model subsequently selected. In contrast, a fixed-effect model with the Mantel--Haenszel method would be selected instead. Moreover, Egger's test was performed to assess publication bias and significant asymmetry considered if *P*\<0.1.[@b22-dddt-13-719] The stability of the treatment effects was evaluated via sensitivity analyses by excluding one study at a time.

Results
=======

Eligible studies and patient characteristics
--------------------------------------------

After screening of 539 initial articles through the electronic databases and another 29 from several other Internet sources, eleven clinical trials were finally enrolled: six RCTs[@b9-dddt-13-719]--[@b11-dddt-13-719],[@b18-dddt-13-719],[@b23-dddt-13-719],[@b24-dddt-13-719] and five Obs trials[@b12-dddt-13-719],[@b13-dddt-13-719],[@b19-dddt-13-719],[@b25-dddt-13-719],[@b26-dddt-13-719] ([Figure 1](#f1-dddt-13-719){ref-type="fig"}). Among these Obs trials, three[@b13-dddt-13-719],[@b19-dddt-13-719],[@b25-dddt-13-719] provided precise details and results for subgroups following propensity-score matching, while one study[@b26-dddt-13-719] reported only propensity-score-matched clinical end points. We analyzed the data from these matched subgroups instead. The main baseline characteristics and dosing regimens of ticagrelor and clopidogrel of the trials are listed in [Tables 1](#t1-dddt-13-719){ref-type="table"} and [2](#t2-dddt-13-719){ref-type="table"}. Assessment of study qualities is described in [Table 1](#t1-dddt-13-719){ref-type="table"}.

Major adverse cardiovascular and cerebrovascular events
-------------------------------------------------------

There was no significant difference between the ticagrelor group and the clopidogrel group with respect to the overall risk of composite MACCEs (OR 0.83, 95% CI 0.66--1.03, *P*=0.091; *I*^2^=49.5%, *P*=0.031; [Figure 2](#f2-dddt-13-719){ref-type="fig"}). Similarly, negative results were also shown in both the RCT (OR 0.79, 95% CI 0.53--1.18, *P*=0.250; *I*^2^=63.0%, *P*=0.019) and Obs subgroups (OR 0.82, 95% CI 0.60--1.12, *P*=0.221; *I*^2^=36.5%, *P*=0.031). Egger's test indicated no publication bias (*P*=0.152).

Cardiovascular death
--------------------

As shown in [Figure 3](#f3-dddt-13-719){ref-type="fig"}, the overall incidence of cardiovascular death was significantly reduced by ticagrelor (OR 0.78, 95% CI 0.68--0.89, *P*\<0.001; *I*^2^=0, *P*=0.575), which might have been due to results of the RCT subgroup (OR 0.79, 95% CI 0.68--0.90, *P*=0.001; *I*^2^=8.8%, *P*=0.356). No publication bias was encountered on Egger's test (*P*=1), and the superiority of ticagrelor was demonstrated by the relevant sensitivity analysis.

Myocardial infarction
---------------------

The incidence of MI did not differ significantly between the ticagrelor group and the clopidogrel group (OR 0.87, 95% CI 0.69--1.10, *P*=0.251; *I*^2^=22.3%, *P*=0.244; [Figure 4](#f4-dddt-13-719){ref-type="fig"}), or the RCT (OR 0.82, 95% CI 0.53--1.27, *P*=0.383; *I*^2^=50.7%, *P*=0.088) and Obs subgroups (OR 0.94, 95% CI 0.64--1.39, *P*=0.762; *I*^2^=0, *P*=0.594). There was no publication bias determined by Egger's test (*P*=0.348).

Stroke
------

As depicted in [Figure 5](#f5-dddt-13-719){ref-type="fig"}, there was no significant difference related to the overall risk of stroke when comparing ticagrelor to clopidogrel (OR 0.88, 95% CI 0.50--1.54, *P*=0.653; *I*^2^=47.5%, *P*=0.055), or between the two subgroups (RCTs, OR 1.16, 95% CI 0.91--1.48, *P*=0.243; *I*^2^=0, *P*=0.488; Obs, OR 0.66, 95% CI 0.17--2.49, *P*=0.536; *I*^2^=68.4%, *P*=0.023). Results from Egger's test suggested no publication bias (*P*=0.754).

Definite/probable stent thrombosis
----------------------------------

The overall incidence of ST differed significantly between the ticagrelor group and the clopidogrel group (OR 0.74, 95% CI 0.59--0.93, *P*=0.009; *I*^2^=0, *P*=0.644; [Figure 6](#f6-dddt-13-719){ref-type="fig"}). Analysis of the RCT group showed similarly positive results (OR 0.73, 95% CI 0.57--0.92, *P*=0.009; *I*^2^=16.4%, *P*=0.274), while no significant difference was obtained in the Obs subgroup (OR 0.86, 95% CI 0.42--1.75, *P*=0.679; *I*^2^=0, *P*=0.573). Egger's test indicated no publication bias (*P*=0.462), and the stability of the results was demonstrated by sensitivity analysis.

All-cause death
---------------

As shown in [Figure 7](#f7-dddt-13-719){ref-type="fig"}, a lower risk of all-cause death was observed in the ticagrelor group (OR 0.81, 95% CI 0.72--0.91, *P*\<0.001; *I*^2^=16.8%, *P*=0.293), which might have been driven by results from the RCT subgroup (OR 0.78, 95% CI 0.69--0.89, *P*\<0.001; *I*^2^=0.1%, *P*=0.406). There was no publication bias found on Egger's test (*P*=0.348). Sensitivity analysis proved the superior effects of ticagrelor.

Safety end points
-----------------

### Bleeding events

Ticagrelor significantly increased the risk of bleeding events, regardless of type: major bleeding (overall, OR 1.36, 95% CI 1.02--1.82, *P*=0.038; *I*^2^=53.7%, *P*=0.022; RCTs, OR 1.05, 95% CI 0.94--1.18, *P*=0.367; *I*^2^=1.6%, *P*=0.397; Obs, OR 1.72, 95% CI 1.07--2.78, *P*=0.026; *I*^2^=44.9%, *P*=0.123; [Figure 8](#f8-dddt-13-719){ref-type="fig"}); minor bleeding (overall, OR 1.43, 95% CI 1.25--1.63, *P*\<0.001; *I*^2^=0, *P*=0.718; RCTs, OR 1.40, 95% CI 1.22--1.62, *P*\<0.001; *I*^2^=0, *P*=0.573; Obs, OR 1.62, 95% CI 1.10--2.40, *P*=0.016; *I*^2^=0, *P*=0.569; [Figure 9](#f9-dddt-13-719){ref-type="fig"}). There was no publication bias evident (*P*=1.000, 0.368, for major and minor bleeding, respectively).

Discussion
==========

The major finding from this meta-analysis was that ticagrelor following PCI significantly reduced the risk of cardiovascular death in patients with ACS, which might potentially lead to a reduction in the incidence of MACCEs. There were no significant reductions in incidence of MI or stroke, but both the risk of major and minor bleeding was increased significantly by ticagrelor. Also, lower occurrence of definite/probable ST and all-cause death was observed in ticagrelor group than the clopidogrel group.

Since the rapid development of interventional techniques applied widely in the clinic, improved clinical outcomes have been reported in patients with ACS.[@b2-dddt-13-719],[@b4-dddt-13-719] Though routine DAPT (aspirin combined with clopidogrel) had been widely used following PCI, the risk of ST and restenosis were still high, leading to higher frequency of death and MI.[@b5-dddt-13-719] The most preferred explanations for this were associated with HTPR.[@b6-dddt-13-719] Replacement of routine clopidogrel with a new potent P2Y12-receptor antagonist (ticagrelor or prasugrel) and high maintenance doses of clopidogrel or triple antiplatelet therapy (TAPT; cilostazol adding to aspirin plus clopidogrel) were tried. In a prior randomized trial,[@b27-dddt-13-719] 2,214 patients with HTPR were analyzed, and high-dose clopidogrel following PCI did not significantly reduce the risk of cardiac death, nonfatal MI, or ST when comparing to standard-dose clopidogrel (2.3% vs 2.3%, *P*=0.97). Additionally, a subgroup analysis from the TRILOGY ACS trial[@b28-dddt-13-719] indicated that the occurrence of cardiovascular death, MI, or stroke among these ACS patients without revascularization did not differ significantly between the prasugrel group and the clopidogrel group at 30-month follow-up. Optimizing an antiplatelet regimen post-PCI for these patients remains a difficult problem. A previous large multicenter, double-blind randomized trial[@b9-dddt-13-719] analyzed 18,624 patients with ACS (ticagrelor vs clopidogrel 9,333 vs 9,291) and indicated that ticagrelor was associated with a significant reduction in the risk of death from vascular causes, MI, or stroke. However, several other RCTs[@b10-dddt-13-719],[@b11-dddt-13-719] and Obs trials,[@b12-dddt-13-719],[@b13-dddt-13-719] also with large samples, demonstrated that there were no significant benefits of ticagrelor in reducing the occurrence of ischemic events among these patients receiving PCI. Furthermore, a recent meta-analysis analyzed 25,805 patients with either stable coronary artery disease or ACS and indicated that ticagrelor following PCI did not significantly reduce the incidence of all-cause mortality, major adverse cardiac events, MI, stroke, or ST, while the risk of bleeding increased instead.[@b14-dddt-13-719],[@b15-dddt-13-719] Another recent meta-analysis showed superiority for ticagrelor in ACS patients with chronic kidney disease without increased bleeding, but \~67.8% of included patients underwent PCI in this study. As a result, this comprehensive meta-analysis focusing on comparisons between ticagrelor and clopidogrel as part of DAPT following PCI for ACS patients was performed.

We previously performed a meta-analysis to evaluate the efficacy and safety of TAPT for patients with complex coronary lesions or suffering from ACS. The incidence of composite major adverse cardiac events (including all-cause mortality, MI, and target vessel revascularization) was lower in patients receiving TAPT rather than routine DAPT.[@b29-dddt-13-719] In this present study, only a tendency toward reduction in the risk of MACCEs (composite of cardiovascular death, MI, and stroke) was observed, which might have resulted from the significantly reduced occurrence of cardiovascular death. As opposed to cilostazol, ticagrelor is a reversible and direct-acting ADP-receptor antagonist, and its main superiority manifests in faster and greater inhibitory effects on platelet aggregation than clopidogrel.[@b7-dddt-13-719],[@b8-dddt-13-719] Though ticagrelor similarly inhibits ADP receptors of subtype P2Y12, it acts differently mainly because of a reversible binding site, making its inhibition differ from clopidogrel.[@b30-dddt-13-719] Cilostazol is a selective inhibitor of phosphodiesterase 3, inhibiting platelet aggregation activated by not only ADP but also epinephrine, collagen, and arachidonic acid, which also serve as major inflammatory response factors.[@b31-dddt-13-719] Therefore, cilostazol was thought to possess possible beneficial effects in diminishing inflammatory response. Of note, severe prothrombotic and inflammatory reactions commonly occur in the acute phase of ACS and would also be obviously ameliorated by the primary PCI procedure, especially in these patients receiving a long-time primary procedure or multiple-stent implantation. Then, platelet aggregation would not get strengthened from the severe inflammatory response during the acute phase of ACS, because it might have been suppressed by cilostazol and subsequently led to better clinical outcomes. These would be possible explanations for why only a tendency toward reduction in risk of MACCEs was acquired with respect to ticagrelor in this meta-analysis.

In addition, results from this meta-analysis demonstrated that ticagrelor can significantly decrease the incidence of definite/probable ST. To the best of our knowledge, the full expansion and apposition of implanted stents meant a successful stenting procedure, which would be much easier to achieve in simple common coronary lesions and subsequently reduce the occurrence of thrombotic events. Furthermore, the definite and potent inhibition of platelet aggregation associated with ticagrelor[@b30-dddt-13-719] would also play a critical role during the process of endothelialization, considered beneficial to prevent restenosis in implanted stents. Based on these potential factors, the incidence of cardiovascular death in the ticagrelor group decreased significantly. Simultaneously, the risk of bleeding, regardless of type, increased significantly in the ticagrelor group in our study, in contrast to the results in the PLATO trial (11.6% vs 11.2%, *P*=0.43).[@b9-dddt-13-719] Possible reasons were thought to be related not only to the definite and potent inhibition of platelet aggregation with respect to ticagrelor itself but also the higher proportion of Asian patients (28.6%) in this meta-analysis, while there were \~5.9% Asians in the PLATO trial instead. It is well known that Asian patients commonly present lower body-mass index values, whereby bleeding might occur more easily under the same dose of ticagrelor. On the other hand, PCI was performed with a radial or femoral approach in these patients and also played as a key role in influencing the final safety results. In the 2018 ESC/EACTS guidelines, radial access was strongly recommended as a standard approach for coronary angiography and PCI (Class IA), due mainly to the significantly reduced incidence of procedure-related major bleeding.[@b32-dddt-13-719]

Limitations
-----------

There still several limitations that should be acknowledged in the current meta-analysis. First, no individual patient data were analyzed and several RCTs had small samples, which might have influenced the final results. Second, accurate details of the PCI procedures were absent from our paper, due mainly to the inadequacy of relevant data, including time of procedure, types of implanted stents, selection of different two-stent techniques for potentially occurred bifurcation lesions, or choice of sheaths of different sizes. Third, there were no definite maintained durations or dosage of ticagrelor for these patients and no limited follow-up in these trials, which might also have swayed the final results. Forth, possible drug adverse reactions reduced tolerance and induced discontinuation of ticagrelor would also be unavoidable interfering factors.

Conclusion
==========

Though only a tendency toward reduction in the risk of MACCEs was observed, ticagrelor as part of DAPT following PCI still seemed to be superior to clopidogrel for ACS patients, mainly because of the significantly decreased incidence of cardiovascular death and ST. However, increased occurrence of bleeding was also observed, and safety might need to be further evaluated. More powerful relevant randomized trials are still warranted to guide clinical decision-making in this area.
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![Forest plots of efficacy and safety end points of the included trials.\
**Notes:** ^\*^Results following propensity-score matching. Weights are from random-effects analysis.\
**Abbreviations:** MACCE, major adverse cardiovascular and cerebrovascular event; Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig2){#f2-dddt-13-719}

![Cardiovascular death.\
**Note:** ^\*^Results following propensity-score matching.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig3){#f3-dddt-13-719}

![Myocardial infarction.\
**Notes:** ^\*^Results following propensity-score matching. Weights are from random-effects analysis.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig4){#f4-dddt-13-719}

![Stroke.\
**Notes:** ^\*^Results following propensity-score matching. Weights are from random-effects analysis.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig5){#f5-dddt-13-719}

![Stent thrombosis.\
**Note:** ^\*^Results following propensity-score matching.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig6){#f6-dddt-13-719}

![All-cause death.\
**Note:** ^\*^Results following propensity-score matching.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig7){#f7-dddt-13-719}

![Major bleeding.\
**Notes:** ^\*^Results following propensity-score matching. Weights are from random-effects analysis.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig8){#f8-dddt-13-719}

![Minor bleeding, associated with ticagrelor compared with clopidogrel.\
**Note:** ^\*^Results following propensity-score matching.\
**Abbreviations:** Obs, observational; RCT, randomized controlled trial.](dddt-13-719Fig9){#f9-dddt-13-719}

###### 

Baseline characteristics of included trials

  Study                                                                      Design   Population   Region            Dosing regimen of ticagrelor                                                  Dosing regimen of clopidogrel                                           Study quality
  -------------------------------------------------------------------------- -------- ------------ ----------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------
                                                                                                                                                                                                                                                                           
  PLATO trial (2009)                                                         RCT      ACS          NA                Loading 180 mg; maintenance 90 mg twice daily                                 Loading 300 mg; maintenance 75 mg/day                                   5
  PHILO trial (2015)                                                         RCT      ACS          East Asia         Loading 180 mg; maintenance 90 mg twice dailyand once-daily placebo tablets   Loading 300 mg; maintenance 75 mg/day andplacebo capsules twice daily   5
  DISPERSE-2 trial (2007)                                                    RCT      NSTE-ACS     NA                Loading 270 mg; maintenance 90 mg twice daily                                 Loading 300 mg; maintenance 75 mg/day                                   4
  Ren et al[@b18-dddt-13-719]                                                RCT      NSTEMI       China             Loading 180 mg; maintenance 90 mg twice daily                                 Loading 300 mg; maintenance 75 mg/day                                   1
  Wang and Wang[@b23-dddt-13-719]                                            RCT      ACS          China             Loading 180 mg; maintenance 90 mg twice daily                                 Loading 300 mg; maintenance 75 mg/day                                   3
  Tang et al[@b24-dddt-13-719]                                               RCT      STEMI        China             Loading 180 mg; maintenance 90 mg twice daily                                 Loading 600 mg; maintenance 75 mg/day                                   3
  [\*](#tfn2-dddt-13-719){ref-type="table-fn"}Chen et al[@b25-dddt-13-719]   Obs      ACS          China             NA                                                                            NA                                                                      5
  [\*](#tfn2-dddt-13-719){ref-type="table-fn"}Wang et al[@b19-dddt-13-719]   Obs      ACS          China             Loading 180 mg; maintenance 90 mg twice daily                                 Loading 300 mg; maintenance 75 mg/day                                   6
  [\*](#tfn2-dddt-13-719){ref-type="table-fn"}Park et al[@b13-dddt-13-719]   Obs      AMI          South Korea       Loading 180 mg; maintenance 90 mg twice daily                                 Loading 300--600 mg; maintenance 75 mg/day                              7
  CHANGE DAPT trial (2017)                                                   Obs      ACS          The Netherlands   Loading 180 mg; maintenance 90 mg twice daily                                 Loading 600 mg; maintenance 75 mg/day                                   8
  Cardio-STEMI registry (2017)                                               Obs      STEMI        Italy             Loading 180 mg; maintenance 90 mg twice daily                                 Loading 150--600 mg; maintenance 75 mg/day                              8

**Notes:** Quality of Obs trials assessed by the Newcastle--Ottawa Scale, with maximum score 9; quality of included RCTs assessed by Jadad score.

Subset following propensity-score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; NA, not available; STEMI, ST-segment-elevation myocardial infarction; NSTE, non-STEMI; Obs, observational; RCT, randomized controlled trial.

###### 

Characteristics of patients' medical histories among included trials

  Study                                                                      Ticagrelor/clopidogrel   Follow-up                                                                                                                       
  -------------------------------------------------------------------------- ------------------------ ------------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ------------
                                                                                                                                                                                                                                      
  PLATO trial (2009)                                                         9,333/9,291              62.0/62.0[\#](#tfn5-dddt-13-719){ref-type="table-fn"}   71.6/71.7   65.8/65.1   24.9/25.1   46.6/46.7   36.0/35.7   4.1/4.4     12 months
  PHILO trial (2015)                                                         401/400                  67/66                                                   76.3/76.7   76.1/72.5   38.4/31.1   78.2/72.3   37.7/39.3   4.5/5.0     12 months
  DISPERSE-2 trial (2007)                                                    334/327                  64/62                                                   61.1/66.4   NA          24.9/24.8   NA          NA          NA          3 months
  Ren et al[@b18-dddt-13-719]                                                149/151                  56/55                                                   68.3/70.1   NA          NA          NA          NA          NA          12 months
  Wang et al[@b23-dddt-13-719]                                               100/100                  79/80[\#](#tfn5-dddt-13-719){ref-type="table-fn"}       69.0/66.0   79.0/82.0   49.0/32.0   84.0/79.0   37.0/41.0   12.0/13.0   12 months
  Tang et al[@b24-dddt-13-719]                                               200/200                  64.4/64.2                                               71.0/73.0   61.0/58.0   29.0/21.0   44.0/37.0   58.0/62.0   NA          6 months
  [\*](#tfn4-dddt-13-719){ref-type="table-fn"}Chen et al[@b25-dddt-13-719]   224/224                  63.8/63.7                                               79.9/79.5   55.4/57.6   37.1/42.9   46.0/44.2   47.3/46.0   39.3/39.3   5.5 months
  [\*](#tfn4-dddt-13-719){ref-type="table-fn"}Wang et al[@b19-dddt-13-719]   779/1,558                60.5/61.0                                               71.1/71.7   57.9/54.5   24.6/23.8   NA          57.3/57.8   2.4/2.4     12 months
  [\*](#tfn4-dddt-13-719){ref-type="table-fn"}Park et al[@b13-dddt-13-719]   1,337/1,337              62.3/62.2                                               77.7/78.9   46.1/46.9   23.7/22.8   11.3/11.3   42.2/42.7   26.7/27.1   6 months
  CHANGE DAPT trial (2017)                                                   1,053/1,009              63.9/62.9                                               71.0/69.6   41.8/42.4   17.7/15.7   36.5/35.7   NA          3.6/4.0     12 months
  Cardio-STEMI registry (2017)                                               142/259                  66/67[\#](#tfn5-dddt-13-719){ref-type="table-fn"}       73.9/69.9   52.8/56.0   22.5/18.5   36.6/39.0   45.8/37.8   7.0/4.6     12 months

**Note:**

Subset following propensity-score matching;

recorded as median.

**Abbreviations:** NA, not available; CRD, chronic renal disease.
